A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)
Latest Information Update: 17 Nov 2023
At a glance
- Drugs Itacitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 10 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Mar 2022 Planned End Date changed from 19 Dec 2024 to 22 Jun 2026.
- 08 Mar 2022 Planned primary completion date changed from 19 Dec 2024 to 22 Jun 2026.